Recommendation of the President – Ozurdex (dexamethasone)

On 22 August 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 117/2025 on the inclusion of the medicinal product Ozurdex (dexamethasone) in the B.70 drug program “Treatment of patients with retinal diseases (ICD-10: H34, H35.3, H36.0)”

Publication in Public Information Bulletin (BIP) >>